Oral semaglutide reduces HbA1c, weight in Type 2 diabetics, study reveals
HQ Team June 8, 2023: A new study analyzing the PIONEER (Peptide Innovation for Early Diabetes Treatment) clinical trials data has revealed the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 8, 2023: A new study analyzing the PIONEER (Peptide Innovation for Early Diabetes Treatment) clinical trials data has revealed the.
HQ Team May 22, 2023: A study to find solutions for treating two new variations of diabetes, type 4 and type 5, is.
Eli Lily sold its sugar-controlling drug to Amphastar Pharmaceuticals for $1.07 billion.
HQ Team April 10, 2023: Cipla Ltd has agreed with Novartis Pharma AG to market and manufacture the Swiss-based company’s Galvus brand for.
Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.
India's Dr. Reddy's Laboratories has divested "certain" non-core dermatology brands of the company to Eris Lifesciences for INR 2.7 billion.
Denmark's Novo Nordisk plans to effect a 75% cut in insulin prices in the U.S. market by January 1, 2024.
Sanofi acquires Provention Bio, and its TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).
Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals US, has received two tentative FDA approvals, one for treating type 2 diabetes and the other.
Kisspeptin hormone could treat hypoactive sexual desire disorder when a person has an extremely low sex drive that causes distress, scientists from the.